Advertisement
Journal Home
Search for

Volume 16, Issue 3, Pages 186-190 (March 2010)


View previous. 8 of 20 View next.

Cancer risk in association with Parkinson disease: A population-based study

Claudia Beckera, Gunnar P. Brobertb, Saga Johanssoncd, Susan S. Jicke, Christoph R. MeieraeCorresponding Author Informationemail address

Received 23 June 2009; received in revised form 23 September 2009; accepted 6 November 2009.

Abstract 

Purpose

Data from large population-based studies on the association between Parkinson disease (PD) and the risk of developing cancer are scarce. We compared the risk of developing incident cancer between patients with or without PD.

Methods

We conducted a population-based follow-up study and a nested case-control analysis using data from the UK-based General Practice Research Database. We included PD patients aged ≥40 years with a first PD diagnosis between 1994 and 2005, and a matched comparison group free of PD. We assessed cancer incidence rates and relative risk estimates (odds ratios [ORs] with 95% confidence intervals [CI]).

Results

The risk of developing cancer overall was lower in PD patients as compared to patients without PD (crude incidence rate ratio 0.77, 95% CI 0.64–0.92). In the nested case-control analysis (adj. OR for all cancers 0.72, 95% CI 0.59–0.87) the risk reduction was strongest for smoking-related cancers (adj. OR 0.47, 95% CI 0.31–0.72). The adjusted OR for hematological malignancies was 0.32 (95% CI 0.14–0.74). Due to small numbers, ORs for other cancer entities did not reach statistical significance.

Conclusions

With the exception of melanoma, PD patients were less likely to develop cancer than individuals without PD in this large observational study.

a Basel Pharmacoepidemiology Unit, Hospital Pharmacy, University Hospital, Spitalstrasse 26, CH-4031 Basel, Switzerland

b AstraZeneca Research & Development, 15185 Södertälje, Sweden

c AstraZeneca Research & Development, 43183 Mölndal, Sweden

d Institute of Medicine, Sahlgrenska Academy, Göteborg University, Sweden

e Boston Collaborative Drug Surveillance Program, Boston University Medical Center, 11 Muzzey Street, Lexington, MA 02421, USA

Corresponding Author InformationCorresponding author at: Basel Pharmacoepidemiology Unit, Hospital Pharmacy, University Hospital, Spitalstrasse 26, CH-4031 Basel, Switzerland. Tel.: +41 61 556 53 69; fax: +41 61 265 88 75.

 The review of this paper was entirely handled by an Associate Editor, Professor En-King Tan.

PII: S1353-8020(09)00277-6

doi:10.1016/j.parkreldis.2009.11.005


View previous. 8 of 20 View next.

Advertisement